Tokio Marine Asset Management Co. Ltd. Acquires 113 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,302 shares of the company’s stock after acquiring an additional 113 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $496,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $30,000. New Covenant Trust Company N.A. bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at about $32,000. EdgeRock Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $35,000. Finally, Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 4.4 %

Shares of Neurocrine Biosciences stock opened at $117.44 on Friday. The stock has a market cap of $11.89 billion, a P/E ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12-month low of $107.84 and a 12-month high of $157.98. The business’s 50 day moving average is $118.50 and its 200-day moving average is $132.66.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NBIX shares. Citigroup upped their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Barclays decreased their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, Oppenheimer boosted their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.